Medica 2026
Nov 16-19, 2026 - Düsseldorf, Germany

Elisa Solution for HHV-6-Reliable and Efficient IgG Antibody Detection

Human herpesvirus 6 (HHV-6) is a prevalent pathogen associated with various clinical manifestations, ranging from the common childhood rash (rosacea) to more severe complications in immunocompromised individuals such as encephalitis, pneumonia, and transplant rejection. Accurate and timely diagnosis is crucial for effective patient management. Serological testing, especially the detection of immunoglobulin G (IgG) antibodies, remains the cornerstone for determining past infections, establishing immune status, and assisting in the diagnosis of active/recurrent infections when combined with IgM testing or PCR. The ability to detect HHV-6 IgG antibodies through reliable and efficient methods is essential for clinical and research purposes.

Human herpesvirus 6.Figure 1. Human herpesvirus 6.

The Challenge of HHV-6 Serology

Diagnosing HHV-6 infection or reactivation can be complex. Direct methods like PCR are highly specific for detecting active viral replication, but they don't provide a complete picture of a patient's immune status or past exposure. Serological methods, which detect antibodies against the virus, are essential for this purpose. However, traditional serological assays often face challenges, including cross-reactivity with other herpesviruses like HHV-7 and cytomegalovirus (CMV), and a lack of standardized, reliable commercial kits. This is where the Enzyme-Linked Immunosorbent Assay (ELISA) emerges as a powerful tool. An ELISA is a plate-based assay designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones. By employing an ELISA for HHV-6 antibody detection, we can overcome many of the limitations of older methods. Our optimized Elisa Solution for HHV-6 IgG Antibody Detection provides a high-performance, user-friendly platform that is specifically designed to meet the demands of modern laboratories.

Technology Platform

Technology Platform

  • Bridging ELISA
  • Indirect ELISA
  • Competitive ELISA
  • Homogeneous ELISA

Sample Type Compatibility

  • Human Serum
  • Human Plasma
  • Other Biological Fluids
  • Clinical Trial Samples

Sensitivity Profile

  • High Sensitivity
  • Ultra-High Sensitivity
  • Regulatory-Compliant
  • Matrix Interference-Optimized

Kit Features

  • Pre-Coated Microplate
  • Complete Reagent Set
  • Automation-Compatible
  • Wide Dynamic Range
  • Rapid Assay Protocol

Key Components & Specifications

Key Features of the Product

  • Accurate quantification: Enables precise quantification of HHV-6 IgG antibody titers to monitor immune responses (e.g., post-transplant or post-vaccination) and track disease progression.
  • High specificity: Utilizes recombinant HHV-6-specific antigens with low homology to other herpesviruses, ensuring reliable HHV-6-specific detection.
  • Excellent sensitivity: Detects low-titer HHV-6 IgG antibodies as early as 2–3 weeks post-infection, improving detection of early or subclinical cases.
  • Flexible sample compatibility: Supports serum, plasma (EDTA, heparin, citrate), reducing patient burden (e.g., pediatric samples).

Specifications

  • Detection target: HHV-6 IgG antibodies (cross-reactive with HHV-6A and HHV-6B) in human serum/plasma.
  • Detection type: Indirect ELISA method.
  • Sample type: Human serum, plasma (EDTA, heparin, citrate anticoagulant).
  • Testing time: ~150 minutes (adjustable based on incubation conditions, typical 2.5-hour workflow).
  • Storage conditions: 2–8°C (unopened kit); -20°C (lyophilized standards/controls).
  • Validity: 12 months (unopened); 6 weeks (opened reagents, 2–8°C).
  • Instrument compatibility: Standard microplate readers.

Intended Use

  • Efficacy monitoring: Tracks changes in HHV-6 IgG titers to evaluate immune reconstitution post-transplant or response to antiviral therapies.
  • Epidemiological study: Maps HHV-6 seroprevalence across populations, age groups, or regions, and investigates subtype distribution (HHV-6A vs. HHV-6B) with add-on reagents.
  • Scientific research: Studies the association between HHV-6 IgG status and chronic diseases (e.g., multiple sclerosis), or explores virus reactivation mechanisms in immunosuppressed settings.

Vaccine Development & Evaluation

  • Immune Response Assessment: Measures HHV-6 IgG antibody titers in clinical trial participants before and after administration of experimental HHV-6 vaccines, providing quantitative data on vaccine-induced immune protection.
  • Durability of Immunity Monitoring: Conducts longitudinal testing of vaccine recipients over months or years to evaluate how long vaccine-induced IgG titers persist, informing vaccine booster schedule recommendations.

Applications in Clinical and Research Settings

Immunosuppressed Patients

Immunosuppressed Patients

For patients undergoing solid organ or hematopoietic stem cell transplantation, HHV-6 reactivation is a significant risk. Routine serological monitoring using ELISA can provide a baseline of their immune status and help identify potential reactivation, especially when used in conjunction with PCR.

Encephalitis and Neurological Disorders

Encephalitis and Neurological Disorders

HHV-6 has been linked to cases of encephalitis, limbic encephalitis, and multiple sclerosis. Detecting HHV-6 IgG antibodies can provide a crucial piece of the diagnostic puzzle, particularly in patients with unexplained neurological symptoms.

Solution for HHV-6-Reliable and Efficient IgG Antibody Detections

ParameterDetails
Product nameHHV-6 IgG ELISA Kit
Sampleserum or plasma
Intended UseFor the detection of IgG antibodies to HHV-6 in human serum isolated from venous or capillary blood.
PrecisionThe interassay variability (between tests) and the intraassay variability (within the test) were determined by testing samples with different OD values.
Performance CharacteristicsThe kit is intended for the qualitative and semiquantitative detection of anti-HHV-6 IgG antibodies in human serum and plasma. Suitable specimens are serum and plasma (heparinised) samples obtained by standard laboratory techniques.
General DescriptionThe kits is intended for serological diagnosis of diseases associated with HHV–6 infection, such as exanthema subitum, acute respiratory illnesses, diarrhoea with fever and febrile seizures in infants, heterophile antibody-negative infectious mononucleosis in children, also interstitial pneumonia, encephalitis, meningitis, hepatitis and aplastic anemia in immunodeficient patients. The presence of IgG anti-HHV-6 antibody reveals the immune status of the patient. Significant rise in anti-HHV-6 IgG antibodies in paired serum samples, taken in acute and convalescent phase of the infection, is indicative of the active infection. The test does not differentiate between HHV-6 subtype A and B.

Quality and Reliability

Our Elisa Solution for HHV-6 IgG Antibody Detection is manufactured under a stringent quality management system to ensure consistency and reliability. Each lot is rigorously tested for performance, stability, and specificity. The kit components are provided in a stable, ready-to-use format with a long shelf life, minimizing waste and ensuring that you always have a high-quality product available. Furthermore, we provide comprehensive technical support to assist our users with any questions regarding the protocol, data analysis, or troubleshooting. Our commitment to quality extends beyond the product itself to ensure a seamless and successful experience for every laboratory.

Advantages

High Sensitivity and Specificity

ELISA can detect low levels of antibodies and is highly specific for HHV-6 IgG, minimizing cross-reactivity with other herpesviruses

Rapid and Quantitative

ELISA provides results within a short time frame (e.g., 60 minutes) and allows for quantitative measurement of antibody levels.

Suitable for Clinical and Research Applications

ELISA is widely used in clinical laboratories and research settings for the diagnosis of HHV-6 infections

Conclusions

The need for a reliable, specific, and efficient method for detecting HHV-6 IgG antibodies is paramount in both clinical and research settings. Our Elisa solution for HHV-6 offers a powerful platform that addresses these needs by combining advanced antigen technology with a user-friendly and robust assay protocol. It provides an indispensable tool for diagnosing HHV-6-related conditions, monitoring at-risk patients, and advancing our understanding of this important human pathogen. By choosing our solution, laboratories can be confident in the accuracy and reliability of their results, leading to better patient care and more impactful research.

Frequently Asked Questions (FAQ)

Antibody FAQs

Still have questions?

Contact Us

This kit uses antigens common to both variants and is designed to detect IgG antibodies against HHV-6 broadly. It does not differentiate between HHV-6A and HHV-6B.

The kit is stable for 12 months from the date of manufacture when stored at 2-8°C.

Yes. Our dedicated team of scientists provides expert technical support to help you achieve optimal assay performance.

Inquiry Basket
loading Loading ......

Inquiry

Inquiry